Papatheodoridis, G. V. Et Al. 2015. EXCELLENT 5 YEAR SURVIVAL IN CAUCASIAN CHRONICHEPATITIS B CHB PATIENTS WITH OR WITHOUT CIRRHOSIS UNDER LONG TERM ENTECAVIR ETV OR TENOFOVIR TDF THERAPY AND THE IMPACT OF HEPATOCELLULAR CARCINOMA HCC. EASL 2015 50TH ANNUAL MEETING OF INTERNATIONAL LIVER CONGRESS .

Papatheodoridis, G. V., Dalekos, G. N., YURTAYDIN, S. C., Buti, M., Sypsa, V., Goulis, I., ... Calleja, J.(2015). EXCELLENT 5 YEAR SURVIVAL IN CAUCASIAN CHRONICHEPATITIS B CHB PATIENTS WITH OR WITHOUT CIRRHOSIS UNDER LONG TERM ENTECAVIR ETV OR TENOFOVIR TDF THERAPY AND THE IMPACT OF HEPATOCELLULAR CARCINOMA HCC . EASL 2015 50TH ANNUAL MEETING OF INTERNATIONAL LIVER CONGRESS

Papatheodoridis, ONUR Et Al. "EXCELLENT 5 YEAR SURVIVAL IN CAUCASIAN CHRONICHEPATITIS B CHB PATIENTS WITH OR WITHOUT CIRRHOSIS UNDER LONG TERM ENTECAVIR ETV OR TENOFOVIR TDF THERAPY AND THE IMPACT OF HEPATOCELLULAR CARCINOMA HCC," EASL 2015 50TH ANNUAL MEETING OF INTERNATIONAL LIVER CONGRESS, 2015

Papatheodoridis, ONUR Et Al. "EXCELLENT 5 YEAR SURVIVAL IN CAUCASIAN CHRONICHEPATITIS B CHB PATIENTS WITH OR WITHOUT CIRRHOSIS UNDER LONG TERM ENTECAVIR ETV OR TENOFOVIR TDF THERAPY AND THE IMPACT OF HEPATOCELLULAR CARCINOMA HCC." EASL 2015 50TH ANNUAL MEETING OF INTERNATIONAL LIVER CONGRESS , 2015

Papatheodoridis, G. V. Et Al. (2015) . "EXCELLENT 5 YEAR SURVIVAL IN CAUCASIAN CHRONICHEPATITIS B CHB PATIENTS WITH OR WITHOUT CIRRHOSIS UNDER LONG TERM ENTECAVIR ETV OR TENOFOVIR TDF THERAPY AND THE IMPACT OF HEPATOCELLULAR CARCINOMA HCC." EASL 2015 50TH ANNUAL MEETING OF INTERNATIONAL LIVER CONGRESS .

@conferencepaper{conferencepaper, author={ONUR KESKİN Et Al. }, title={EXCELLENT 5 YEAR SURVIVAL IN CAUCASIAN CHRONICHEPATITIS B CHB PATIENTS WITH OR WITHOUT CIRRHOSIS UNDER LONG TERM ENTECAVIR ETV OR TENOFOVIR TDF THERAPY AND THE IMPACT OF HEPATOCELLULAR CARCINOMA HCC}, congress name={EASL 2015 50TH ANNUAL MEETING OF INTERNATIONAL LIVER CONGRESS}, city={}, country={}, year={2015}}